This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
Questions about our CME?
Questions about our CME?

This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

ExpertPerspectives: The Why and How for Combination Basal Insulin + GLP-1RA Therapy in Type 2 Diabetes

ExpertPerspectives: The Why and How for Combination Basal Insulin + GLP-1RA Therapy in Type 2 Diabetes

Format

Meeting Coverage

Time to Complete

1.50 hours

Released

October 5, 2018

Expires

October 4, 2019
Add to Queue


Maximum Credits

1.50 / AMA PRA Category 1 CreditsTM
1.50 / CNE Contact Hours
1.50 / CE for Nurse Practitioners
1.50 / CE for Pharmacists (0.15 CEUs)

Accredited Provider

Provided by the Annenberg Center for Health Sciences at Eisenhower

Commercial Supporter

This activity is supported by an educational grant from Novo Nordisk Inc.

Program Description

John Anderson, MD, and Vivian Fonseca, MD, provide their clinical insights into the rapidly evolving use of combined basal insulin and glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy for the treatment of patients with type 2 diabetes mellitus (T2DM). Based upon the pathophysiologic rationale for combining basal insulin and a GLP-1RA, Drs. Anderson and Fonseca discuss the benefits and limitations of adding a GLP-1RA vs prandial insulin in patients with inadequate glycemic control with basal insulin.

Content Areas

  • Unmet needs
  • Experience with basal insulin/GLP-1RA
  • FRC basal insulin/GLP-1RAs
  • Insulin degludec/liraglutide (DUAL)
  • Insulin glargine/lixisenatide (LixiLan-L, -O)
  • Using FRC basal insulin/GLP-1RAs
  • Case studies

Intended Audience

This activity is intended for primary care physicians, endocrinologists, nurse practitioners, nurses, pharmacists, and other clinicians with an interest in type 2 diabetes.

Educational Objectives

At the conclusion of this activity, participants should be better able to:

  • Describe the unmet needs of patients with type 2 diabetes
  • Outline the role of basal insulin and GLP-1RAs as described in current guidelines
  • Compare the benefits and limitations of GLP-1RA vs prandial insulin as add-on to basal insulin
  • Describe the glycemic and nonglycemic outcomes observed with fixed-ratio basal insulin/GLP-1RA combination products
  • Initiate and titrate fixed-ratio basal insulin/GLP-1RA combination products

Conflict Of Interest Disclosure Policy

It is the policy of the Annenberg Center for Health Sciences to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All faculty and planners participating in sponsored programs are expected to identify and reference off-label product use and disclose any relationship with those supporting the activity or any others with products or services available within the scope of the topic being discussed in the educational presentation.

The Annenberg Center for Health Sciences assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CE/CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CE/CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.

In accordance with the Accreditation Council for Continuing Medical Education Standards, parallel documents from other accrediting bodies, and Annenberg Center for Health Sciences policy, the following disclosures have been made:

Faculty

Vivian A. Fonseca, MD
Tullis-Tulane Alumni Chair in Diabetes
Professor of Medicine
Chief, Section of Endocrinology
Tulane University School of Medicine
New Orleans, Louisiana

Dr. Fonseca discloses the following:
Research Support: Bayer, Boehringer Ingelheim
Consultant: Asahi, AstraZeneca, Eli Lilly, Intarcia, Novo Nordisk, Sanofi-Aventis, Takeda

John E. Anderson, MD
The Frist Clinic
Nashville, Tennessee

Dr. Anderson discloses the following:
Consultant: Abbot, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck, Novo Nordisk, Sanofi
Speakers Bureau: AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Sanofi
Shareholder: NuSirt Biopharma

Accredited Provider Disclosures

Charles Willis, Director of Continuing Education, consults for Pfizer, Inc; all other staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

Publishing Staff Disclosures

Gregory Scott, PharmD, RPh (medical writer) has nothing to disclose.
Heather Gibson, BSN, MSN (peer reviewer) has nothing to disclose.
Christopher Flores, MD (peer reviewer) has nothing to disclose.

Credit

1.50

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statement

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.50 AMA PRA Category 1 CreditsTM .  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit

1.50

Type

CNE Contact Hour(s)

Accreditation Statement

Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Designation Statement

A maximum of 1.50 contact hours may be earned for successful completion of this activity.

Provider is approved by the California Board of Registered Nursing, Provider #13664, for 1.50 contact hours. To receive credit for education contact hours outside of the state of California, please check with your state board of registered nursing for reciprocity.

Credit

1.50

Type

CE for Nurse Practitioners

Accreditation Statement


Annenberg Center for Health Sciences at Eisenhower is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 040207.

Designation Statement

This program is accredited for 1.50 contact hours. Program ID #5651.

Credit

1.50

Type

CE for Pharmacists

Accreditation Statement

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program has been assigned ACPE Universal Program # 0797-0000-18-063-H01-P. This program is designated for up to 1.50 contact hours (0.15 CEUs) of continuing pharmacy education credit.

This activity will address professional practice gaps in knowledge.

Disclosure of Unlabeled Use

The faculty for this activity have disclosed that there will be no discussion about the use of products for non-FDA approved applications.

Disclaimer

The ideas and opinions presented in this educational activity are those of the faculty and do not necessarily reflect the views of the Annenberg Center and/or its agents. As in all educational activities, we encourage practitioners to use their own judgment in treating and addressing the needs of each individual patient, taking into account that patient’s unique clinical situation. The Annenberg Center disclaims all liability and cannot be held responsible for any problems that may arise from participating in this activity or following treatment recommendations presented.

Instructions

This activity is an online enduring material. Successful completion is achieved by reading and/or viewing the material, reflecting on its implications for your practice, and completing the assessment component.

Please note: The content of this activity is housed on the website of our educational partner, Annenberg Center for Health Sciences at Eisenhower, and requires you to leave myCME and register on the Annenberg website.

Your certificate will be saved on the Annenberg website only and cannot be accessed in your myCME CME History. Please go to https://education.annenberg.net and sign in to access your certificate in the future.

Contact Information

For help or questions about this Internet activity, please contact Annenberg Continuing Education:
ce@annenberg.net
Annenberg Center for Health Sciences
39000 Bob Hope Drive
Dinah Shore Building
Rancho Mirage, CA 92270
Phone: 760-773-4500
Fax: 760-773-4513
8 AM – 5 PM, Pacific Time, Monday – Friday

Privacy Policy

Annenberg Center for Health Sciences respects your privacy. We don’t share information you give us, or have the need to share this information in the normal course of providing the services and information you may request. If there should be a need or request to share this information, we will do so only with your explicit permission. See Privacy Statement and other information at http://www.annenberg.net/privacy-policy/

myCME privacy policy
Add to Queue